Search alternatives:
significant use » significant cause (Expand Search), significant i.e (Expand Search), significantly used (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
use based » rule based (Expand Search), case based (Expand Search), one based (Expand Search)
Showing 61 - 80 results of 129,414 for search '(( significant use based ) OR ( significant ((non decrease) OR (point decrease)) ))', query time: 0.78s Refine Results
  1. 61
    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with fecal tests).

    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with fecal tests). by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 62
    PRISMA checklist.

    PRISMA checklist. by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 63
    PRISMA flow diagram.

    PRISMA flow diagram. by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 64
    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with serology).

    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with serology). by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 65
    Main characteristics of included papers.

    Main characteristics of included papers. by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 66
    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with fecal tests), stratified by quality of the studies.

    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with fecal tests), stratified by quality of the studies. by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 67
    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with fecal tests), stratified by number of ivermectin rounds.

    Forest plot displaying <i>Strongyloides stercoralis</i> prevalence before and after the intervention (assessment with fecal tests), stratified by number of ivermectin rounds. by Giacomo Stroffolini (11716410)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 68
    Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines.

    Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines. by Sarah A. Head (6066398)

    Published 2021
    “…(B) SRRM4 target exons with respect to their average PSI in normal tissues. Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
    Save to List
    Saved in:
  9. 69
    Treatment with pan-PKC inhibitor Gö-6983 resulted in a non-significant decrease in <i>GRK6</i> promoter activity.

    Treatment with pan-PKC inhibitor Gö-6983 resulted in a non-significant decrease in <i>GRK6</i> promoter activity. by Maike Stegen (8578665)

    Published 2021
    Save to List
    Saved in:
  10. 70
    Point cloud fusion instance effect.

    Point cloud fusion instance effect. by Hongliang Zou (20707270)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    SLE decreases risk for hormonal cancers.

    SLE decreases risk for hormonal cancers. by Deborah K. Johnson (10001156)

    Published 2021
    Save to List
    Saved in:
  12. 72
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  13. 73
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 80
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: